Article

Drug-gene interaction screens coupled to tumour data analyses identify the most clinically-relevant cancer vulnerabilities driving sensitivity to PARP inhibition

2022-07-31

Abstract excerpt

Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) are currently indicated for the treatment of ovarian, breast, pancreatic and prostate cancers harbouring mutations in the tumour suppressor genes BRCA1 or BRCA2 . In the case of ovarian and prostate cancers, their classification as homologous recombination repair (HRR) deficient (HRD) or mutated (HRRm) also makes PARPi an available treatment option beyond BR...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 48c3cea4-eee4-5870-8d46-f934137ba5b6
DOI: 10.1101/2022.07.29.501846

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Drug-gene interaction screens coupled to tumour data analyses identify the most clinically-relevant cancer vulnerabilities driving sensitivity to PARP inhibitionDOI 10.1101/2022.07.29.501846Read

Drug–gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP InhibitionSemantic proximity Read

CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancerSemantic proximity Read

Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancerSemantic proximity Read

CRISPR screening identifies novel PARP inhibitor classification based on distinct base excision repair pathway dependenciesSemantic proximity Read

The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA RepairSemantic proximity Read

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistanceSemantic proximity Read

A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivitiesSemantic proximity Read

CRISPR screens guide the way for PARP and ATR inhibitor biomarker discoverySemantic proximity Read

DNA-Damage-Repair Gene Alterations in Genitourinary MalignanciesSemantic proximity Read

Genetic landscape of homologous recombination repair genes in early-onset/familial prostate cancer patientsSemantic proximity Read

Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspectiveSemantic proximity Read